{"ticker": {"uuid": "da73c975-c1ee-4ff9-bcca-beef8886cba9", "symbol": "SLN", "name": "Silence Therapeutics PLC", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Silence Therapeutics rated speculative Buy on promising polycythemia vera drug with key Phase 2 data due 2026", "summary": "Willow Tree Research initiated coverage of Silence Therapeutics with a speculative Buy rating, citing the potential of its mRNAi drug divesiran (SLN124) for polycythemia vera. The drug's platform offers infrequent dosing and strong target knockdown, with promising early Phase 1 d", "url": "https://pluang.com/en/news-feed/silence-therapeutics-data-pv-bisa-bangkitkan-saham-beli-spesulatif", "source_name": "Pluang", "published_at": "2026-07-13T10:40:34", "published_display": "13 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics: PV Data Could Wake The Stock (Initiating Buy) (NASDAQ:SLN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNT0R5VjZ0ZExSdTB5WWRIeGxvSXVYYUFoRXZfMWU4Q0hhT3R5cFdGcDZ4cENQYWl1ZzNPODludVQ5QjlkSDAxWjYtZ1o3d3JKTlhQUW14R3F2MWNFaFlxX2xzcmYyb3lBQlMwYllpY1lsaFdEQWQ4Z2FzTXhsWnJDeGUyNGpvNlNHSTczYnQyYWpIOUNHQkhLdUZ6Zmt3c2hLeG5YN2NwRXhrMTQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-12T17:21:11+00:00", "published_display": "12 Jul 2026 17:21", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A Silence Therapeutics Plc For: 8 July By Investing.com", "summary": "The article reports on a Form 13D/A filing by Silence Therapeutics Plc for July 8th. This filing is a regulatory document typically used to disclose beneficial ownership of a company's shares. The article itself contains minimal content beyond the title and a stock symbol, indica", "url": "https://za.investing.com/news/stock-market-news/form-13da-silence-therapeutics-plc-for-8-july-93CH-4360190", "source_name": "Investing.com South Africa", "published_at": "2026-07-09T08:41:44", "published_display": "09 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Richard Griffiths updates Silence Therapeutics (SLN) holdings in latest 13D/A", "summary": "Richard Griffiths has filed an Amendment No. 10 to his Schedule 13D, reporting a 21.7% beneficial ownership in Silence Therapeutics plc, totaling 30,844,458 ordinary shares. This update reflects open-market sales of 1,544,374 American Depositary Shares (ADSs) between June 29 and ", "url": "https://www.stocktitan.net/sec-filings/SLN/schedule-13d-a-silence-therapeutics-plc-amended-major-shareholder-rep-51c890af154c.html", "source_name": "Stock Titan", "published_at": "2026-07-08T11:09:17", "published_display": "08 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Griffiths trims Silence Therapeutics (SLN) stake with 1.54M ADS sales", "summary": "Richard Ian Griffiths, a 10% owner of Silence Therapeutics (SLN), reported the sale of 1,544,374 American Depositary Shares (ADSs) across six open-market transactions between June 29 and July 6, 2026. These sales were conducted indirectly through entities like Cream Capital Limit", "url": "https://www.stocktitan.net/sec-filings/SLN/form-4-silence-therapeutics-plc-insider-trading-activity-65edd9f8104c.html", "source_name": "Stock Titan", "published_at": "2026-07-07T12:40:47", "published_display": "07 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics plc (SLN) Initiated at Overweight as Analyst Highlights siRNA Pipeline Potential", "summary": "Cantor Fitzgerald initiated coverage of Silence Therapeutics plc (NASDAQ:SLN) with an Overweight rating, highlighting its siRNA pipeline and the potential of divesiran for polycythemia vera. The firm sees over 160% upside based on its valuation, ahead of Phase 2 results for dives", "url": "https://www.insidermonkey.com/blog/silence-therapeutics-plc-sln-initiated-at-overweight-as-analyst-highlights-sirna-pipeline-potential-1792083/", "source_name": "Insider Monkey", "published_at": "2026-07-01T07:10:11", "published_display": "01 Jul 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Silence Therapeutics Plc - American Depository Share \u2013 NASDAQ:SLN", "summary": "The article focuses on the \"Price to earnings forward\" financial metric for Silence Therapeutics Plc (NASDAQ: SLN). It identifies the company as an American Depository Share listed on the Nasdaq Stock Market. The content is presented within the TradingView platform, noting that t", "url": "https://www.tradingview.com/symbols/NASDAQ-SLN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T19:40:30", "published_display": "28 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Silence Therapeutics Plc - American Depository Share \u2013 NASDAQ:SLN", "summary": "This article provides the enterprise value to EBIT forward for Silence Therapeutics Plc (NASDAQ:SLN). It appears to be a financial data point from TradingView's platform, offering financial insights for the company. The content itself seems to be a placeholder for specific numeri", "url": "https://www.tradingview.com/symbols/NASDAQ-SLN/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T06:40:09", "published_display": "27 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Silence Therapeutics Plc - American Depository Share \u2013 NASDAQ:SLN", "summary": "The article displays the \"Price to sales forward\" metric for Silence Therapeutics Plc - American Depository Share (NASDAQ: SLN) on TradingView. It indicates that the market was closed with no trades. The article is a financial data page rather than a detailed news report, providi", "url": "https://www.tradingview.com/symbols/NASDAQ-SLN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T16:09:38", "published_display": "26 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics plc Actuals & Estimates (OTC:SLNCF)", "summary": "The article provides an overview of Silence Therapeutics, Plc. (SLNCF) stock, detailing its current price, historical highs and lows, market capitalization, volatility, and financial performance. It highlights the stock's recent price increases and answers frequently asked questi", "url": "https://www.tradingview.com/symbols/OTC-SLNCF/forecast-actuals-and-estimates/?category=income_statement", "source_name": "TradingView", "published_at": "2026-06-26T08:41:01", "published_display": "26 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Silence Therapeutics Plc - American Depository Share \u2013 NASDAQ:SLN", "summary": "This article provides a financial snapshot of Silence Therapeutics Plc - American Depository Share (NASDAQ: SLN), focusing on its enterprise value to revenue forward metric. It details the company's financial data available on TradingView, along with general market information.", "url": "https://www.tradingview.com/symbols/NASDAQ-SLN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:40:02", "published_display": "26 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics PLC Sponsored ADR Actuals & Estimates (NASDAQ:SLN)", "summary": "This page on TradingView provides financial actuals and estimates for Silence Therapeutics Plc (NASDAQ:SLN), an American Depository Share. Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation", "url": "https://www.tradingview.com/symbols/NASDAQ-SLN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:40:02", "published_display": "26 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Silence Therapeutics Plc - American Depository Share \u2013 NASDAQ:SLN", "summary": "This article presents the \"Price to book forward\" financial metric for Silence Therapeutics Plc (NASDAQ: SLN), an American Depository Share. The content is primarily a data point from TradingView's financial section, offering a specific valuation metric for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-SLN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T21:39:36", "published_display": "25 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Silence Therapeutics stock surging today? By Investing.com", "summary": "Silence Therapeutics (SLN) stock surged over 16% in mid-day trading after Cantor Fitzgerald initiated coverage with an Overweight rating, deeming the shares undervalued. The optimism stems from the potential of its lead asset, divesiran, particularly its Phase 2 SANRECO trial in ", "url": "https://ng.investing.com/news/stock-market-news/why-is-silence-therapeutics-stock-surging-today-93CH-2572589", "source_name": "Investing.com Nigeria", "published_at": "2026-06-25T16:41:13", "published_display": "25 Jun 2026 16:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Silence Therapeutics stock surging today?", "summary": "Silence Therapeutics PLC (SLN) stock surged over 16% in mid-day trading after Cantor Fitzgerald initiated coverage with an Overweight rating, citing the undervaluation of its lead asset, divesiran. The optimism is driven by the upcoming Phase 2 SANRECO trial results for polycythe", "url": "https://m.investing.com/news/stock-market-news/why-is-silence-therapeutics-stock-surging-today-93CH-4758718?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-25T15:40:02", "published_display": "25 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 87, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains?", "summary": "Silence Therapeutics (SLN) shares surged 26.0% to $9.16, driven by investor confidence in its long-term growth prospects, particularly for its lead candidate, divesiran, an siRNA therapy for polycythemia vera. The company anticipates topline results from its SANRECO phase II stud", "url": "https://sg.finance.yahoo.com/news/silence-therapeutics-sln-surges-26-114800896.html", "source_name": "Market source", "published_at": "2026-06-25T07:48:00", "published_display": "25 Jun 2026 07:48", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics stock jumps on Cantor Fitzgerald upgrade", "summary": "Silence Therapeutics PLC (NASDAQ:SLN) shares surged 18.6% after Cantor Fitzgerald initiated coverage with an Overweight rating. Analyst Prakhar Agrawal highlighted the company's clinical-stage siRNA drug pipeline, particularly focusing on divesiran, a TMPRSS6 siRNA treatment for ", "url": "https://m.investing.com/news/stock-market-news/silence-therapeutics-stock-jumps-on-cantor-fitzgerald-upgrade-93CH-4758621?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-24T15:59:28", "published_display": "24 Jun 2026 15:59", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald initiates Silence Therapeutics stock at overweight", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNTVFTWjRtaGhFeElTYjJoeEZtQUlXNlo4dnZNNGYtSnZRMklqWkVmWUZ2MW1NWE1wcm5pVVpmdWx1dGxRQkN3XzY0anpTZkRjd2RmVGtjUi15NnVIVGFPNVRESGVlWGF2Tjc0Snk2QVZMMWNGQjJybUZvN2RkQVR6NDY3TmpwQ0hGSGJlUWNEQnRrRVpkUXI2QzlhTE1TeUNGNEpIenE5S2hqR1dHbWhaVUZ3eXVFcVJFRzNxaUloRTdqMGE3NXJR?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Silence Therapeutics Stock Soaring Wednesday? - Silence Therapeutics (NASDAQ:SLN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPRWNkZGd3RHNlQjBZUnZwR3A3ajNHZmNjT3RXRlZpcWZCU3NYZGpNUkpnZVFfVmdzV0Z3c2drVDlyUVdZZFVheElVdVdzWnBYMU90anh2VnVidHk4T1N5QWVSaWhJU21iNE1xSzc3WTh2UU1kdFV4c0lmZXdNYlhkbjNkUmg3aXNxcTM1c2VkZk4tNG10N1dBcy1vRThyQmNfLUtuejI3SUVnT0RfQjhxNkc2Z0g1T08xRnBRZDVncW9YUFhvLXQtOA?oc=5", "source_name": "Benzinga", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coiled Therapeutics appoints biotech veteran Craig Tooman to board", "summary": "Coiled Therapeutics, an AIM-listed clinical-stage oncology company, has appointed Craig Tooman as an independent non-executive director. Tooman brings over 30 years of pharmaceutical and biotechnology leadership experience and has been instrumental in raising significant capital ", "url": "https://uk.finance.yahoo.com/news/coiled-therapeutics-appoints-biotech-veteran-065600799.html", "source_name": "Market source", "published_at": "2026-06-24T06:40:52", "published_display": "24 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Silence Therapeutics plc For: 23 June By Investing.com", "summary": "This article is a Form 8K filing for Silence Therapeutics plc, dated June 23, 2026. It includes a disclaimer from Investing.com regarding the risks associated with trading financial instruments and cryptocurrencies, emphasizing that data may not be real-time or accurate.", "url": "https://m.za.investing.com/news/stock-market-news/form-8k-silence-therapeutics-plc-for-23-june-93CH-4340824?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-24T01:40:52", "published_display": "24 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics updates corporate presentation highlighting Divesiran Phase 2 topline timing and pipeline progress", "summary": "Silence Therapeutics has issued an updated corporate presentation detailing key advancements in its pipeline. The company expects topline results for its Divesiran Phase 2 SANRECO trial in Q3 2026 and highlighted progress in multiple siRNA programs, including SLN312 and other pre", "url": "https://www.tradingview.com/news/tradingview:0e0f8f26b5ee5:0-silence-therapeutics-updates-corporate-presentation-highlighting-divesiran-phase-2-topline-timing-and-pipeline-progress/", "source_name": "TradingView", "published_at": "2026-06-24T00:39:47", "published_display": "24 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics (NASDAQ: SLN) details divesiran, SLN312 and obesity siRNA plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQcUNoZUVaSWRhSFpzUGs3RUJ6bFFwVjhlTHM2WEQ0SFlQS2FteG5lM3QtNllrOUpwMkNEdUIzLTAzdUZYWjlDOG1NdlNqT2JqX2lwbWJIU0kycE1uUllmbWxaOVhJWkpqOTg2dE5iemo2aHNKdks1NndpRUczZlNiVW1RYTVxaDlub1RTYlcwN0t2QnNKeWl5UjdDcWt5WGU3VGxEcWVUNGM2N2FnV1J5UVFB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics PLC (SLN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Silence Therapeutics PLC (SLN) has an earnings forecast score of 8.00, ranking 163rd in the Biotechnology & Medical Research industry. Analysts have set an average price target of $30.00, with a high of $75.00 and a low of $4.00. Based on ratings from 6 analysts, most recommend a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-sln/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T23:11:33", "published_display": "18 Jun 2026 23:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics shareholders approve all resolutions at annual meeting", "summary": "Silence Therapeutics plc announced that all nine resolutions proposed at its 2026 Annual General Meeting of Shareholders were approved. These resolutions included the re-appointment of directors, approval of executive compensation, ratification of PricewaterhouseCoopers LLP as au", "url": "https://m.uk.investing.com/news/sec-filings/silence-therapeutics-shareholders-approve-all-resolutions-at-annual-meeting-93CH-4731789?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-18T00:39:22", "published_display": "18 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Silence Therapeutics (SLN) Is Building the Divesiran Case Around Fewer Blood Draws in Polycythemia Vera", "summary": "Silence Therapeutics (SLN) is developing divesiran, an experimental RNA-based treatment for polycythemia vera, a rare blood cancer. The company presented Phase 1 SANRECO study data showing that divesiran significantly reduced the need for frequent blood draws in patients. Silence", "url": "https://www.insidermonkey.com/blog/how-silence-therapeutics-sln-is-building-the-divesiran-case-around-fewer-blood-draws-in-polycythemia-vera-1783032/", "source_name": "Insider Monkey", "published_at": "2026-06-17T11:16:00", "published_display": "17 Jun 2026 11:16", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics shareholders approve all resolutions at annual meeting By Investing.com", "summary": "Silence Therapeutics plc announced that all nine resolutions proposed at its 2026 Annual General Meeting of Shareholders were approved. Key approvals included the re-appointment of directors Rhonda Hellums and James Ede-Golightly, the advisory approval of executive officer compen", "url": "https://ng.investing.com/news/sec-filings/silence-therapeutics-shareholders-approve-all-resolutions-at-annual-meeting-93CH-2561745", "source_name": "Investing.com Nigeria", "published_at": "2026-06-17T01:08:55", "published_display": "17 Jun 2026 01:08", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics (SLN) investors approve directors, pay and auditors at 2026 AGM", "summary": "Silence Therapeutics plc shareholders approved all nine resolutions at its 2026 Annual General Meeting. This included the re-appointment of directors Rhonda Hellums and James Ede-Golightly, advisory approval of executive compensation, and the re-appointment of PricewaterhouseCoop", "url": "https://www.stocktitan.net/sec-filings/SLN/8-k-silence-therapeutics-plc-reports-material-event-f9a5f6f1ddea.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:39:18", "published_display": "16 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data", "summary": "Silence Therapeutics shares increased after the company released positive follow-up data from its Phase 1 SANRECO study for divesiran, a drug targeting polycythemia vera. The data showed potential improvements in symptoms and quality of life, along with reduced phlebotomy use. Wi", "url": "https://www.sahmcapital.com/news/content/silence-therapeutics-stock-rises-on-positive-blood-cancer-drug-data-2026-06-12", "source_name": "Sahm", "published_at": "2026-06-15T01:40:28", "published_display": "15 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera", "summary": "Silence Therapeutics presented follow-up data from its Phase 1 SANRECO study for divesiran, a potential best-in-class siRNA therapy for polycythemia vera (PV), at EHA 2026. The data showed durable reductions in phlebotomy use that persisted after the final dose, along with improv", "url": "https://www.businesswire.com/news/home/20260611005104/en/Silence-Therapeutics-Highlights-Follow-Up-Data-at-EHA-2026-Demonstrating-Durable-Efficacy-and-Potential-Best-in-Class-Profile-for-Divesiran-in-Polycythemia-Vera", "source_name": "Business Wire", "published_at": "2026-06-11T23:09:53", "published_display": "11 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics presents divesiran trial data at EHA", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNSy1zemNUd1FSX21kNUdRdmxsc0tMTlFTNk5uWDdSOTdUNEI2czJTYUZVZTM2X2ZlQ0FKNjNKNVluTm1wa0oxSjEyTDV0Y2pQTy1Ha09rOTJ4Mnp2amFTdGdwTXVwRnRWTG9LeE9yMElUZWRoX19vZFNReWllTVkya2prWXdNTy1ycGoxaGJvVUozYVpNV09wdTVhQmVVUzBNTElSTWNWUUFzR0R3akswRTNBZHo?oc=5", "source_name": "Investing.com", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oligonucleotide Therapeutics Market Size Report, 2026-2033", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPUUxfX2J0aDFMTmhHWWRNV1o0YmJlN2NQR0MzdXluRUZtaWxpcnA1RXhIZVh3V0lsUGl0TEh2NnJNbjRnRENaTTY3LWdqN1NQSGNCaGZuRk01VDlMVFpqUFlaYnlfZ0pGRkExdkxwN2VVUEVpOG5ycGtWMTVJWDV3RHlyTk5ETExhNHJEZ2lIN09oR1ZscWJNWFFn?oc=5", "source_name": "Grand View Research", "published_at": "2026-05-26T12:43:31+00:00", "published_display": "26 May 2026 12:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Silence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNbGhjM0ExZlFBV082OE1tVkphUC1wU05PeTFjX0ZQc1RMbnFpNjBKaERGaFpQd05kOXhldmR0aUtydDV2RHZvdkdBOFlEXzBHcGdIc1MzOUNFeG1CTG1DUTNBaDdYY0pJSVBrUWliRTRjMDFTQUQ5SllvRnMxaGlDdXMxdGdNSlVQQktGUkFNaWFGTjRRZ3pheHllM3JtUDQ?oc=5", "source_name": "Market source", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With Silence Therapeutics Up 24%, Insider Buyers Count Their Returns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Silence Therapeutics (NASDAQ:SLN) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNakZjZGJBNDd5TVc3Y0hpbFJEc3EzTGNkaUk3QXJRa2tQZGFqR19jWnprVHJfMTd6RkhyVHJMbUlGZEN1Mjc1ZlMtMUduX2Q1eUZvaWg5WnBfc0std2sxRzlia3ZyU0o5eW1qU3RyTzRxS00tcmtUdmVXY3U1d3p4b1kwMllZaDVYSjVVSFg5RFNrdlRhaFg1bWJVMFhSYWJSZW1GcA?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Small Interfering RNA (siRNA) Therapeutics Market Size to Hit USD 528.78 Billion by 2035", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxOZXh3S2p5cGNtLXl5UWdNS3lwT2l1dnRfb1FUVG14emgxQ2liSEtONDJsc2JTa0V1VVk0aEZ6eEZfWmNaREE4a3U0SE1lejFPUmw4R0FLS2ZrQUJfVHZEOXloclhQalVaWms2TUI4dHV5bVZWX05mQzdidktQTC1HOTFR?oc=5", "source_name": "Precedence Research", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPck5Kb3VqSUVoSGtjQnNBQzYwY3BHbWVpQVB4elpFWXEydF90STZvcTdRNXo4d2F3LXNWclJRVi03ZXNBVllNeE5ZZS1vQTk5UGplLTNTSmFtakxfTmxPdmxmWXg4WWxubzJGa21CUE5Ib25Na2gtRnd2LU93czlHVnkzOVRKRUt4U1Bzaw?oc=5", "source_name": "Market source", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revenues Working Against Silence Therapeutics plc's (NASDAQ:SLN) Share Price Following 27% Dive", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxNeDVMd2Z6c09rSHN4TE1lWGYxZi1TdmNObUNJNHdKX1lWTW9nN1FCU1QySmNYb1R6dUplcm82cm14WEVjaDlSQXFwVTYxZkQxZEpUOENRVl9jenRfRmU4LURSVFdudUJpY0pjd3BaMjlUMkRZWVR1MkxrZjVqYUZmUDd6REcyZU85YlhobHJycGRCNkpsdmlSVTZhcFA4bjRmTzQxaEpBRE1sZ3VVbXpsa2J1YjlXaWxlTFg2QktvTTdBaXlPOUVGek4yOE5IY2tmbThvSjZySXZZMS1UQ1c3M3pPNGtIbTdI0gHuAUFVX3lxTE9BU2xuaUdCZTlubmhKVlRoWWxuNDdyc1hHX3B3MzVHV2RaR0JyTEd3WkNaTFVKOC1jSjg2djljTlExS2l6NXVnRlpQY2lHLXJ5c3Bqc19jQ3k1b1A3RHlWaVFoa2VYRWxaZWtqVV9RR3VVM29sc0xhREY5VVV5bGxSUDZPaWlkRl9NOWd4QVJQSTYwcTkyUnNIUXB4U2VQZ2htUG5wTnBTSndsWTVVUjZzVmQ0cEFvR2x0MWFwODBDaVlBMHpUTVpHRW9UWFhXQTBMdlRoVVdWQkIwT19CMzBJTTlwUDc3YWUweGxucFE?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-31T08:00:00+00:00", "published_display": "31 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics (SLN) Stock Forecast and Price Target 2026 $SLN", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTFBHUEI4YUV2VXlaQTNRd1pYZFdZaWd1NV92aGZEaHM2RExoRHpxN3hLaG5KMlRCbERhNmZuOFNoZVhLakxXanA5SHV4ZzNwSjltX0ZTTWhOQlVaeGdzZENJNmhPWlk?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T14:39:36+00:00", "published_display": "11 May 2024 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Silence Therapeutics rated speculative Buy on promising polycythemia vera drug with key Phase 2 data due 2026", "summary": "Willow Tree Research initiated coverage of Silence Therapeutics with a speculative Buy rating, citing the potential of its mRNAi drug divesiran (SLN124) for polycythemia vera. The drug's platform offers infrequent dosing and strong target knockdown, with promising early Phase 1 d", "url": "https://pluang.com/en/news-feed/silence-therapeutics-data-pv-bisa-bangkitkan-saham-beli-spesulatif", "source_name": "Pluang", "published_at": "2026-07-13T10:40:34", "published_display": "13 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics: PV Data Could Wake The Stock (Initiating Buy) (NASDAQ:SLN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNT0R5VjZ0ZExSdTB5WWRIeGxvSXVYYUFoRXZfMWU4Q0hhT3R5cFdGcDZ4cENQYWl1ZzNPODludVQ5QjlkSDAxWjYtZ1o3d3JKTlhQUW14R3F2MWNFaFlxX2xzcmYyb3lBQlMwYllpY1lsaFdEQWQ4Z2FzTXhsWnJDeGUyNGpvNlNHSTczYnQyYWpIOUNHQkhLdUZ6Zmt3c2hLeG5YN2NwRXhrMTQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-12T17:21:11+00:00", "published_display": "12 Jul 2026 17:21", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A Silence Therapeutics Plc For: 8 July By Investing.com", "summary": "The article reports on a Form 13D/A filing by Silence Therapeutics Plc for July 8th. This filing is a regulatory document typically used to disclose beneficial ownership of a company's shares. The article itself contains minimal content beyond the title and a stock symbol, indica", "url": "https://za.investing.com/news/stock-market-news/form-13da-silence-therapeutics-plc-for-8-july-93CH-4360190", "source_name": "Investing.com South Africa", "published_at": "2026-07-09T08:41:44", "published_display": "09 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Richard Griffiths updates Silence Therapeutics (SLN) holdings in latest 13D/A", "summary": "Richard Griffiths has filed an Amendment No. 10 to his Schedule 13D, reporting a 21.7% beneficial ownership in Silence Therapeutics plc, totaling 30,844,458 ordinary shares. This update reflects open-market sales of 1,544,374 American Depositary Shares (ADSs) between June 29 and ", "url": "https://www.stocktitan.net/sec-filings/SLN/schedule-13d-a-silence-therapeutics-plc-amended-major-shareholder-rep-51c890af154c.html", "source_name": "Stock Titan", "published_at": "2026-07-08T11:09:17", "published_display": "08 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Griffiths trims Silence Therapeutics (SLN) stake with 1.54M ADS sales", "summary": "Richard Ian Griffiths, a 10% owner of Silence Therapeutics (SLN), reported the sale of 1,544,374 American Depositary Shares (ADSs) across six open-market transactions between June 29 and July 6, 2026. These sales were conducted indirectly through entities like Cream Capital Limit", "url": "https://www.stocktitan.net/sec-filings/SLN/form-4-silence-therapeutics-plc-insider-trading-activity-65edd9f8104c.html", "source_name": "Stock Titan", "published_at": "2026-07-07T12:40:47", "published_display": "07 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics plc (SLN) Initiated at Overweight as Analyst Highlights siRNA Pipeline Potential", "summary": "Cantor Fitzgerald initiated coverage of Silence Therapeutics plc (NASDAQ:SLN) with an Overweight rating, highlighting its siRNA pipeline and the potential of divesiran for polycythemia vera. The firm sees over 160% upside based on its valuation, ahead of Phase 2 results for dives", "url": "https://www.insidermonkey.com/blog/silence-therapeutics-plc-sln-initiated-at-overweight-as-analyst-highlights-sirna-pipeline-potential-1792083/", "source_name": "Insider Monkey", "published_at": "2026-07-01T07:10:11", "published_display": "01 Jul 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Silence Therapeutics Plc - American Depository Share \u2013 NASDAQ:SLN", "summary": "The article focuses on the \"Price to earnings forward\" financial metric for Silence Therapeutics Plc (NASDAQ: SLN). It identifies the company as an American Depository Share listed on the Nasdaq Stock Market. The content is presented within the TradingView platform, noting that t", "url": "https://www.tradingview.com/symbols/NASDAQ-SLN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T19:40:30", "published_display": "28 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Silence Therapeutics Plc - American Depository Share \u2013 NASDAQ:SLN", "summary": "This article provides the enterprise value to EBIT forward for Silence Therapeutics Plc (NASDAQ:SLN). It appears to be a financial data point from TradingView's platform, offering financial insights for the company. The content itself seems to be a placeholder for specific numeri", "url": "https://www.tradingview.com/symbols/NASDAQ-SLN/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T06:40:09", "published_display": "27 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Silence Therapeutics Plc - American Depository Share \u2013 NASDAQ:SLN", "summary": "The article displays the \"Price to sales forward\" metric for Silence Therapeutics Plc - American Depository Share (NASDAQ: SLN) on TradingView. It indicates that the market was closed with no trades. The article is a financial data page rather than a detailed news report, providi", "url": "https://www.tradingview.com/symbols/NASDAQ-SLN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T16:09:38", "published_display": "26 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics plc Actuals & Estimates (OTC:SLNCF)", "summary": "The article provides an overview of Silence Therapeutics, Plc. (SLNCF) stock, detailing its current price, historical highs and lows, market capitalization, volatility, and financial performance. It highlights the stock's recent price increases and answers frequently asked questi", "url": "https://www.tradingview.com/symbols/OTC-SLNCF/forecast-actuals-and-estimates/?category=income_statement", "source_name": "TradingView", "published_at": "2026-06-26T08:41:01", "published_display": "26 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Silence Therapeutics Plc - American Depository Share \u2013 NASDAQ:SLN", "summary": "This article provides a financial snapshot of Silence Therapeutics Plc - American Depository Share (NASDAQ: SLN), focusing on its enterprise value to revenue forward metric. It details the company's financial data available on TradingView, along with general market information.", "url": "https://www.tradingview.com/symbols/NASDAQ-SLN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:40:02", "published_display": "26 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics PLC Sponsored ADR Actuals & Estimates (NASDAQ:SLN)", "summary": "This page on TradingView provides financial actuals and estimates for Silence Therapeutics Plc (NASDAQ:SLN), an American Depository Share. Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation", "url": "https://www.tradingview.com/symbols/NASDAQ-SLN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:40:02", "published_display": "26 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Silence Therapeutics Plc - American Depository Share \u2013 NASDAQ:SLN", "summary": "This article presents the \"Price to book forward\" financial metric for Silence Therapeutics Plc (NASDAQ: SLN), an American Depository Share. The content is primarily a data point from TradingView's financial section, offering a specific valuation metric for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-SLN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T21:39:36", "published_display": "25 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Silence Therapeutics stock surging today? By Investing.com", "summary": "Silence Therapeutics (SLN) stock surged over 16% in mid-day trading after Cantor Fitzgerald initiated coverage with an Overweight rating, deeming the shares undervalued. The optimism stems from the potential of its lead asset, divesiran, particularly its Phase 2 SANRECO trial in ", "url": "https://ng.investing.com/news/stock-market-news/why-is-silence-therapeutics-stock-surging-today-93CH-2572589", "source_name": "Investing.com Nigeria", "published_at": "2026-06-25T16:41:13", "published_display": "25 Jun 2026 16:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Silence Therapeutics stock surging today?", "summary": "Silence Therapeutics PLC (SLN) stock surged over 16% in mid-day trading after Cantor Fitzgerald initiated coverage with an Overweight rating, citing the undervaluation of its lead asset, divesiran. The optimism is driven by the upcoming Phase 2 SANRECO trial results for polycythe", "url": "https://m.investing.com/news/stock-market-news/why-is-silence-therapeutics-stock-surging-today-93CH-4758718?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-25T15:40:02", "published_display": "25 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 87, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains?", "summary": "Silence Therapeutics (SLN) shares surged 26.0% to $9.16, driven by investor confidence in its long-term growth prospects, particularly for its lead candidate, divesiran, an siRNA therapy for polycythemia vera. The company anticipates topline results from its SANRECO phase II stud", "url": "https://sg.finance.yahoo.com/news/silence-therapeutics-sln-surges-26-114800896.html", "source_name": "Market source", "published_at": "2026-06-25T07:48:00", "published_display": "25 Jun 2026 07:48", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics stock jumps on Cantor Fitzgerald upgrade", "summary": "Silence Therapeutics PLC (NASDAQ:SLN) shares surged 18.6% after Cantor Fitzgerald initiated coverage with an Overweight rating. Analyst Prakhar Agrawal highlighted the company's clinical-stage siRNA drug pipeline, particularly focusing on divesiran, a TMPRSS6 siRNA treatment for ", "url": "https://m.investing.com/news/stock-market-news/silence-therapeutics-stock-jumps-on-cantor-fitzgerald-upgrade-93CH-4758621?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-24T15:59:28", "published_display": "24 Jun 2026 15:59", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald initiates Silence Therapeutics stock at overweight", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNTVFTWjRtaGhFeElTYjJoeEZtQUlXNlo4dnZNNGYtSnZRMklqWkVmWUZ2MW1NWE1wcm5pVVpmdWx1dGxRQkN3XzY0anpTZkRjd2RmVGtjUi15NnVIVGFPNVRESGVlWGF2Tjc0Snk2QVZMMWNGQjJybUZvN2RkQVR6NDY3TmpwQ0hGSGJlUWNEQnRrRVpkUXI2QzlhTE1TeUNGNEpIenE5S2hqR1dHbWhaVUZ3eXVFcVJFRzNxaUloRTdqMGE3NXJR?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Silence Therapeutics Stock Soaring Wednesday? - Silence Therapeutics (NASDAQ:SLN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPRWNkZGd3RHNlQjBZUnZwR3A3ajNHZmNjT3RXRlZpcWZCU3NYZGpNUkpnZVFfVmdzV0Z3c2drVDlyUVdZZFVheElVdVdzWnBYMU90anh2VnVidHk4T1N5QWVSaWhJU21iNE1xSzc3WTh2UU1kdFV4c0lmZXdNYlhkbjNkUmg3aXNxcTM1c2VkZk4tNG10N1dBcy1vRThyQmNfLUtuejI3SUVnT0RfQjhxNkc2Z0g1T08xRnBRZDVncW9YUFhvLXQtOA?oc=5", "source_name": "Benzinga", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coiled Therapeutics appoints biotech veteran Craig Tooman to board", "summary": "Coiled Therapeutics, an AIM-listed clinical-stage oncology company, has appointed Craig Tooman as an independent non-executive director. Tooman brings over 30 years of pharmaceutical and biotechnology leadership experience and has been instrumental in raising significant capital ", "url": "https://uk.finance.yahoo.com/news/coiled-therapeutics-appoints-biotech-veteran-065600799.html", "source_name": "Market source", "published_at": "2026-06-24T06:40:52", "published_display": "24 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Silence Therapeutics plc For: 23 June By Investing.com", "summary": "This article is a Form 8K filing for Silence Therapeutics plc, dated June 23, 2026. It includes a disclaimer from Investing.com regarding the risks associated with trading financial instruments and cryptocurrencies, emphasizing that data may not be real-time or accurate.", "url": "https://m.za.investing.com/news/stock-market-news/form-8k-silence-therapeutics-plc-for-23-june-93CH-4340824?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-24T01:40:52", "published_display": "24 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics updates corporate presentation highlighting Divesiran Phase 2 topline timing and pipeline progress", "summary": "Silence Therapeutics has issued an updated corporate presentation detailing key advancements in its pipeline. The company expects topline results for its Divesiran Phase 2 SANRECO trial in Q3 2026 and highlighted progress in multiple siRNA programs, including SLN312 and other pre", "url": "https://www.tradingview.com/news/tradingview:0e0f8f26b5ee5:0-silence-therapeutics-updates-corporate-presentation-highlighting-divesiran-phase-2-topline-timing-and-pipeline-progress/", "source_name": "TradingView", "published_at": "2026-06-24T00:39:47", "published_display": "24 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics (NASDAQ: SLN) details divesiran, SLN312 and obesity siRNA plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQcUNoZUVaSWRhSFpzUGs3RUJ6bFFwVjhlTHM2WEQ0SFlQS2FteG5lM3QtNllrOUpwMkNEdUIzLTAzdUZYWjlDOG1NdlNqT2JqX2lwbWJIU0kycE1uUllmbWxaOVhJWkpqOTg2dE5iemo2aHNKdks1NndpRUczZlNiVW1RYTVxaDlub1RTYlcwN0t2QnNKeWl5UjdDcWt5WGU3VGxEcWVUNGM2N2FnV1J5UVFB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics PLC (SLN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Silence Therapeutics PLC (SLN) has an earnings forecast score of 8.00, ranking 163rd in the Biotechnology & Medical Research industry. Analysts have set an average price target of $30.00, with a high of $75.00 and a low of $4.00. Based on ratings from 6 analysts, most recommend a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-sln/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T23:11:33", "published_display": "18 Jun 2026 23:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics shareholders approve all resolutions at annual meeting", "summary": "Silence Therapeutics plc announced that all nine resolutions proposed at its 2026 Annual General Meeting of Shareholders were approved. These resolutions included the re-appointment of directors, approval of executive compensation, ratification of PricewaterhouseCoopers LLP as au", "url": "https://m.uk.investing.com/news/sec-filings/silence-therapeutics-shareholders-approve-all-resolutions-at-annual-meeting-93CH-4731789?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-18T00:39:22", "published_display": "18 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Silence Therapeutics (SLN) Is Building the Divesiran Case Around Fewer Blood Draws in Polycythemia Vera", "summary": "Silence Therapeutics (SLN) is developing divesiran, an experimental RNA-based treatment for polycythemia vera, a rare blood cancer. The company presented Phase 1 SANRECO study data showing that divesiran significantly reduced the need for frequent blood draws in patients. Silence", "url": "https://www.insidermonkey.com/blog/how-silence-therapeutics-sln-is-building-the-divesiran-case-around-fewer-blood-draws-in-polycythemia-vera-1783032/", "source_name": "Insider Monkey", "published_at": "2026-06-17T11:16:00", "published_display": "17 Jun 2026 11:16", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics shareholders approve all resolutions at annual meeting By Investing.com", "summary": "Silence Therapeutics plc announced that all nine resolutions proposed at its 2026 Annual General Meeting of Shareholders were approved. Key approvals included the re-appointment of directors Rhonda Hellums and James Ede-Golightly, the advisory approval of executive officer compen", "url": "https://ng.investing.com/news/sec-filings/silence-therapeutics-shareholders-approve-all-resolutions-at-annual-meeting-93CH-2561745", "source_name": "Investing.com Nigeria", "published_at": "2026-06-17T01:08:55", "published_display": "17 Jun 2026 01:08", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics (SLN) investors approve directors, pay and auditors at 2026 AGM", "summary": "Silence Therapeutics plc shareholders approved all nine resolutions at its 2026 Annual General Meeting. This included the re-appointment of directors Rhonda Hellums and James Ede-Golightly, advisory approval of executive compensation, and the re-appointment of PricewaterhouseCoop", "url": "https://www.stocktitan.net/sec-filings/SLN/8-k-silence-therapeutics-plc-reports-material-event-f9a5f6f1ddea.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:39:18", "published_display": "16 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data", "summary": "Silence Therapeutics shares increased after the company released positive follow-up data from its Phase 1 SANRECO study for divesiran, a drug targeting polycythemia vera. The data showed potential improvements in symptoms and quality of life, along with reduced phlebotomy use. Wi", "url": "https://www.sahmcapital.com/news/content/silence-therapeutics-stock-rises-on-positive-blood-cancer-drug-data-2026-06-12", "source_name": "Sahm", "published_at": "2026-06-15T01:40:28", "published_display": "15 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera", "summary": "Silence Therapeutics presented follow-up data from its Phase 1 SANRECO study for divesiran, a potential best-in-class siRNA therapy for polycythemia vera (PV), at EHA 2026. The data showed durable reductions in phlebotomy use that persisted after the final dose, along with improv", "url": "https://www.businesswire.com/news/home/20260611005104/en/Silence-Therapeutics-Highlights-Follow-Up-Data-at-EHA-2026-Demonstrating-Durable-Efficacy-and-Potential-Best-in-Class-Profile-for-Divesiran-in-Polycythemia-Vera", "source_name": "Business Wire", "published_at": "2026-06-11T23:09:53", "published_display": "11 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics presents divesiran trial data at EHA", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNSy1zemNUd1FSX21kNUdRdmxsc0tMTlFTNk5uWDdSOTdUNEI2czJTYUZVZTM2X2ZlQ0FKNjNKNVluTm1wa0oxSjEyTDV0Y2pQTy1Ha09rOTJ4Mnp2amFTdGdwTXVwRnRWTG9LeE9yMElUZWRoX19vZFNReWllTVkya2prWXdNTy1ycGoxaGJvVUozYVpNV09wdTVhQmVVUzBNTElSTWNWUUFzR0R3akswRTNBZHo?oc=5", "source_name": "Investing.com", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oligonucleotide Therapeutics Market Size Report, 2026-2033", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPUUxfX2J0aDFMTmhHWWRNV1o0YmJlN2NQR0MzdXluRUZtaWxpcnA1RXhIZVh3V0lsUGl0TEh2NnJNbjRnRENaTTY3LWdqN1NQSGNCaGZuRk01VDlMVFpqUFlaYnlfZ0pGRkExdkxwN2VVUEVpOG5ycGtWMTVJWDV3RHlyTk5ETExhNHJEZ2lIN09oR1ZscWJNWFFn?oc=5", "source_name": "Grand View Research", "published_at": "2026-05-26T12:43:31+00:00", "published_display": "26 May 2026 12:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNbGhjM0ExZlFBV082OE1tVkphUC1wU05PeTFjX0ZQc1RMbnFpNjBKaERGaFpQd05kOXhldmR0aUtydDV2RHZvdkdBOFlEXzBHcGdIc1MzOUNFeG1CTG1DUTNBaDdYY0pJSVBrUWliRTRjMDFTQUQ5SllvRnMxaGlDdXMxdGdNSlVQQktGUkFNaWFGTjRRZ3pheHllM3JtUDQ?oc=5", "source_name": "Market source", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With Silence Therapeutics Up 24%, Insider Buyers Count Their Returns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Silence Therapeutics (NASDAQ:SLN) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNakZjZGJBNDd5TVc3Y0hpbFJEc3EzTGNkaUk3QXJRa2tQZGFqR19jWnprVHJfMTd6RkhyVHJMbUlGZEN1Mjc1ZlMtMUduX2Q1eUZvaWg5WnBfc0std2sxRzlia3ZyU0o5eW1qU3RyTzRxS00tcmtUdmVXY3U1d3p4b1kwMllZaDVYSjVVSFg5RFNrdlRhaFg1bWJVMFhSYWJSZW1GcA?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Small Interfering RNA (siRNA) Therapeutics Market Size to Hit USD 528.78 Billion by 2035", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxOZXh3S2p5cGNtLXl5UWdNS3lwT2l1dnRfb1FUVG14emgxQ2liSEtONDJsc2JTa0V1VVk0aEZ6eEZfWmNaREE4a3U0SE1lejFPUmw4R0FLS2ZrQUJfVHZEOXloclhQalVaWms2TUI4dHV5bVZWX05mQzdidktQTC1HOTFR?oc=5", "source_name": "Precedence Research", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPck5Kb3VqSUVoSGtjQnNBQzYwY3BHbWVpQVB4elpFWXEydF90STZvcTdRNXo4d2F3LXNWclJRVi03ZXNBVllNeE5ZZS1vQTk5UGplLTNTSmFtakxfTmxPdmxmWXg4WWxubzJGa21CUE5Ib25Na2gtRnd2LU93czlHVnkzOVRKRUt4U1Bzaw?oc=5", "source_name": "Market source", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revenues Working Against Silence Therapeutics plc's (NASDAQ:SLN) Share Price Following 27% Dive", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-31T08:00:00+00:00", "published_display": "31 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silence Therapeutics (SLN) Stock Forecast and Price Target 2026 $SLN", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTFBHUEI4YUV2VXlaQTNRd1pYZFdZaWd1NV92aGZEaHM2RExoRHpxN3hLaG5KMlRCbERhNmZuOFNoZVhLakxXanA5SHV4ZzNwSjltX0ZTTWhOQlVaeGdzZENJNmhPWlk?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T14:39:36+00:00", "published_display": "11 May 2024 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 48, "sentiment_summary": {"positive": 16, "negative": 1, "neutral": 31, "score": 58, "total": 48, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 12.45, "count": 22}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 14}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 9.09, "latest_week": "2026-07-10", "one_week_move": -12.5, "four_week_move": 35.9, "twelve_week_move": 20.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.343723, "market_dynamics_buy_signal": false, "relative_strength": 25.966916, "fair_value_gap": -14.3, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 47.5604, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-12.5% over one week, +35.9% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "TradingView", "count": 9}, {"label": "Investing.com", "count": 5}, {"label": "simplywall.st", "count": 5}, {"label": "Stock Titan", "count": 4}, {"label": "Investing.com South Africa", "count": 2}, {"label": "Insider Monkey", "count": 2}, {"label": "Investing.com Nigeria", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 40}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 22}, {"label": "Earnings", "count": 14}, {"label": "Analyst action", "count": 5}, {"label": "Regulatory and legal", "count": 4}, {"label": "Deals and strategy", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "40", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-12.5% over one week, +35.9% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Silence Therapeutics rated speculative Buy on promising polycythemia vera drug with key Phase 2 data due 2026"}], "updated_at": "2026-07-16T07:04:13.277813+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}